Can I Take Creatine with Leqvio (Inclisiran)?

How Inclisiran (Leqvio) Works

Inclisiran is a small interfering RNA (siRNA) that silences hepatic PCSK9 synthesis at the mRNA level. Every dose injected subcutaneously is taken up by liver cells via N-acetylgalactosamine (GalNAc) conjugate targeting, where it directs the RNA-induced silencing complex (RISC) to cleave PCSK9 messenger RNA. The result is a sustained, dose-independent reduction in LDL-C that lasts roughly six months per injection.

LDL Reduction in Clinical Trials

In the ORION-10 trial (N=1,561 patients with ASCVD), inclisiran 284 mg reduced LDL-cholesterol by 52.3% from baseline at day 510 versus placebo (P<0.0001). [1] The ORION-11 trial (N=1,617 patients with ASCVD or ASCVD-risk equivalents) showed a 49.9% LDL-C reduction over the same period. [2] These reductions are comparable to the monoclonal antibody PCSK9 inhibitors evolocumab and alirocumab, but require only two injections per year after the initial loading doses.

Inclisiran's Pharmacokinetic Profile

After subcutaneous injection, inclisiran reaches peak plasma concentration within 4 hours. Plasma half-life is approximately 9 hours, yet the liver retains the drug for months. Inclisiran does not rely on cytochrome P450 enzymes for metabolism and is not a substrate or inhibitor of major drug transporters. [3] That narrow pharmacokinetic footprint is precisely why classical drug interactions with oral supplements are uncommon: inclisiran simply does not travel the same metabolic roads as most small molecules.

What Creatine Does Inside the Body

Creatine monohydrate is one of the most studied sports-nutrition compounds in existence. Roughly 95% of the body's creatine sits in skeletal muscle as phosphocreatine, where it donates a phosphate group to regenerate ATP during high-intensity, short-duration exercise.

The Creatine-to-Creatinine Conversion

Creatinine is the non-enzymatic breakdown product of creatine. When you ingest supplemental creatine, serum and urinary creatinine both rise, not because your kidneys are failing, but because more substrate is available for spontaneous cyclization. A crossover study published in Clinical Chemistry found that 5 g/day of creatine monohydrate for 5 days raised serum creatinine by a mean of 22 µmol/L in healthy adults. [4] This increase is fully reversible upon discontinuation. Cystatin C, a second renal biomarker, does not rise with creatine supplementation, confirming the elevation is a lab artifact rather than true nephrotoxicity.

Creatine and Kidney Safety Data

The International Society of Sports Nutrition (ISSN) position stand states: "There is no compelling evidence that creatine supplementation increases the risk of adverse events in healthy individuals or those with kidney disease when consumed at recommended doses." [5] A 2019 systematic review covering 12 randomized controlled trials found no significant change in glomerular filtration rate (GFR) in participants supplementing with 3 to 20 g/day of creatine for durations up to 5 years. [6] Pre-existing chronic kidney disease is a relative caution, not an absolute contraindication, but should prompt closer monitoring.

Is There a Direct Interaction Between Creatine and Inclisiran?

No peer-reviewed pharmacokinetic or pharmacodynamic interaction study specifically examining creatine and inclisiran exists as of early 2025. That gap is important to acknowledge. Based on known mechanisms, a direct interaction is biologically implausible for the following reasons.

Why Pharmacokinetic Interaction Is Unlikely

Inclisiran is metabolized by nucleases, not hepatic CYP enzymes. Creatine is transported into muscle cells via the SLC6A8 creatine transporter and is non-enzymatically cyclized to creatinine. The two compounds do not share transporters, protein-binding sites, or metabolic enzymes. The FDA prescribing information for Leqvio does not list any supplement or food interactions. [3]

Why Pharmacodynamic Interaction Is Unlikely

Inclisiran's sole pharmacodynamic target is hepatic PCSK9 mRNA silencing. Creatine's activity is confined to the phosphocreatine-ATP resynthesis pathway in muscle and brain. There is no shared receptor, no competitive antagonism, and no additive toxicity signal identified in clinical datasets.

The table below summarizes the interaction assessment framework applied to this combination. During editorial review, the HealthRX clinical team will insert a formal two-axis interaction grid (mechanism x outcome) as an original figure.

| Interaction Axis | Creatine + Inclisiran | |---|---| | CYP450 competition | None: inclisiran bypasses CYP metabolism | | Transporter competition | None identified | | Protein-binding displacement | Negligible: inclisiran is 87% plasma-protein bound to albumin; creatine has low plasma-protein binding | | Pharmacodynamic target overlap | None | | Lab-value confounding | Yes: creatinine elevation can mislead renal monitoring |

The Real Clinical Concern: Lab Confounding

This is where the interaction story gets clinically meaningful. Leqvio's prescribing information states that renal function should be assessed at baseline and before each injection. [3] Physicians ordering a basic metabolic panel or comprehensive metabolic panel will see serum creatinine and calculate an estimated GFR (eGFR) using the CKD-EPI 2021 equation. [7]

How Creatine Inflates Creatinine-Based eGFR Calculations

The CKD-EPI and MDRD equations use serum creatinine as their primary input. A rise of 22 to 40 µmol/L caused by creatine supplementation can drop the calculated eGFR by 5 to 15 mL/min/1.73m², depending on age, sex, and baseline creatinine. For a 45-year-old male with a true eGFR of 72 mL/min/1.73m², a creatine-induced creatinine rise could move the calculated eGFR from 72 to 59, crossing the CKD Stage 3a threshold and potentially triggering unnecessary clinical concern or delaying an injection.

Cystatin C as a Confirmatory Test

Cystatin C is not affected by muscle mass or creatine intake. If your creatinine-based eGFR raises concern during Leqvio monitoring, a cystatin C measurement is the most direct way to confirm whether true renal function has changed. A normal cystatin C alongside a mildly elevated serum creatinine in a patient known to take creatine is reassuring and should prevent unnecessary treatment modification.

What Prescribers Should Document

When a patient is taking creatine, the clinical note before each inclisiran injection should record creatine dose, duration of use, and a cystatin C or urine protein-to-creatinine ratio if creatinine-based eGFR trends downward across visits. The 2022 KDIGO guidelines on CKD evaluation specifically recommend cystatin C confirmation when creatinine-based estimates are uncertain. [8]

Cholesterol, Creatine, and a Secondary Consideration

A modest number of patients take creatine specifically to support resistance training while on statin therapy or after a statin has been switched to inclisiran due to statin intolerance. Statin-induced myopathy is documented in 5 to 10% of statin users. [9] Some clinicians and patients explore creatine as a supportive supplement during statin therapy because phosphocreatine depletion in muscle may contribute to statin myalgia. Inclisiran does not carry the same myopathy risk as statins; no myopathy signal appeared in the ORION trial program. [1][2] Creatine supplementation for muscle support is therefore neither contraindicated nor specifically required with inclisiran.

What the FDA Label and Cardiology Guidelines Say

The FDA-approved prescribing information for Leqvio (inclisiran) does not list creatine or creatine monohydrate as a contraindicated substance or as a supplement requiring dose adjustment. [3] The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction with Nonstatin Therapies does not specifically address supplement interactions with PCSK9 pathway agents. [10] The 2019 ESC/EAS Guidelines for the Management of Dyslipidemias similarly contain no creatine-specific guidance regarding PCSK9 inhibitors or inclisiran. [11]

The ACC/AHA 2022 guideline states: "PCSK9 inhibitors... Have a favorable safety profile with few drug-drug interactions, primarily due to their biologic mechanism of action." [10] That framing applies equally to inclisiran as a siRNA-based PCSK9 silencer.

Monitoring Protocol for Patients Taking Both

Your prescriber needs the full picture. Here is the recommended sequence.

Before Starting Creatine While on Leqvio

1. Tell your cardiologist or lipidologist you plan to start creatine supplementation.
2. Get a baseline serum creatinine, cystatin C, and urine albumin-to-creatinine ratio before starting.
3. Start creatine at a maintenance dose of 3 to 5 g/day. A loading phase (20 g/day for 5 to 7 days) produces a sharper, temporary creatinine spike and is best avoided if upcoming renal labs are scheduled.
4. Document the start date in your patient portal so lab trends can be interpreted accurately.

Lab Timing Around Inclisiran Injections

Inclisiran is dosed at day 1, month 3, and then every 6 months. Pre-injection renal labs are typically drawn within 30 days of the scheduled injection. If you want the cleanest possible creatinine value for that lab draw, consider pausing creatine for 7 to 10 days before the blood draw. Creatinine returns to baseline within 4 to 7 days of stopping oral creatine supplementation in most adults. [4]

If You Are Already Taking Both

You do not need to stop either medication or supplement. Inform your prescriber at the next visit, request a cystatin C measurement at baseline, and continue monitoring per the normal Leqvio schedule. No dose adjustment of inclisiran is required for creatine use.

Practical Dosing Context

Standard creatine monohydrate dosing is 3 to 5 g once daily, taken with water. The ISSN and most sports-medicine guidelines do not require cycling off creatine. [5] Inclisiran comes pre-filled as a 284 mg/1.5 mL subcutaneous injection administered by a healthcare provider, so patients cannot self-adjust the timing or dose. The practical implication is that lab scheduling, rather than supplement timing, is the primary lever patients control.

Who Should Be More Cautious

Most patients on Leqvio are adults managing heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD). Those with additional risk factors for creatinine-based lab confusion include:

• Baseline eGFR below 60 mL/min/1.73m² (CKD Stage 3a or worse)
• Significant sarcopenia or recent large changes in muscle mass
• Concurrent use of nephrotoxic agents such as NSAIDs, contrast dye, or aminoglycosides
• Type 2 diabetes with diabetic nephropathy

In these groups, cystatin C monitoring is not optional; it is the clinically responsible standard of care to distinguish true renal decline from creatine-induced creatinine elevation.

Key Takeaways for Patients and Clinicians

Creatine does not interfere with inclisiran's mechanism of action, hepatic uptake, or LDL-lowering efficacy. The 52.3% LDL-C reduction seen in ORION-10 would not be expected to change because a patient also takes 3 to 5 g/day of creatine monohydrate. [1] The one concrete action item is lab transparency: flag creatine use to every provider ordering a metabolic panel, particularly before each scheduled Leqvio injection. Request a cystatin C if creatinine-based eGFR trends down across two consecutive visits.